No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapseH. Moses Murdock, Robert J. Soiffer, Marlise R. Luskin et al.|Blood Advances|2025Cited by 3
Post Allogeneic Stem Cell Transplant Outcomes Following Response to Hypomethylating Agent Therapy in Myelodysplastic Syndromes Are Predicted By Persistent International Prognostic Scoring System-Molecular RiskStacey M. Frumm, Maximilian Stahl, Haesook T. Kim et al.|Blood|2023Cited by 0
A Simple Prediction Model of Outcomes after Allogeneic Hematopoietic Stem Cell Transplant (HCT) in Myelodysplastic Syndromes Using HCT-Comorbidity Index, Cytogenetic Risk, and Platelet CountStacey M. Frumm, Maximilian Stahl, Haesook T. Kim et al.|Blood|2023Cited by 0
Redefining Clinical Response Criteria in Myelodysplastic Syndromes to Better Forecast Post-Transplant OutcomesLuis E. Aguirre, Maximilian Stahl, Haesook T. Kim et al.|Blood|2024Cited by 0
Integrating Functional Marrow Reserve and Molecular Risk Improves Prediction of Post-Transplant Outcomes in MDSLuis E. Aguirre, Rami S. Komrokji, Haesook T. Kim et al.|Blood Neoplasia|2026Cited by 0